Single dose coronavirus vaccine enters late stage testing

24 September 2020

The first coronavirus vaccine candidate requiring a single dose has entered into global Phase III trials, recruiting 60,000 people in South America, the USA and Europe.

Johnson & Johnson (NYSE: JNJ) said it had launched the ENSEMBLE trial testing JNJ-78436735, after positive interim results from a Phase I/IIa study. Shares in the company rose slightly in pre-market trading.

J&J is also scaling up its manufacturing capacity, and said it remains on track to meet its goal of providing one billion doses of a vaccine each year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK